PharmAust teams up with leading cancer research institute on MPL drug candidate
PharmAust (ASX:PAA), a clinical-stage oncology company, has revealed its new collaboration with Dr Doug Fairlie, a leading cancer researcher based at Victoria’s prestigious Olivia Newton-John Cancer Research Institute (ONJCRI).
This collaboration was formed in order to better understand how PAA’s leading clinical candidate, Monepantel (MPL), is able to kill cancer cells.
An additional critical aim here is to identify drug combinations that improve MPL’s potency against different types of cancers.
In turn, these outcomes will be used to support and accelerate MPL’s clinical development strategies in humans and dogs.
Moreover, the collaboration has been awarded a $50,000 Innovation Connections Grant from the Commonwealth Department of Industry, Innovation and Science – a clear recognition of this partnership’s commercial potential.
“We are excited about the potential of this project which builds upon the long-term research interests of our laboratory,” said Dr Fairlie.
The project is in its early stages therefore investors considering this stock for their portfolio, should seek professional financial advice.
PAA CEO, Dr Richard Hopkins, said: “This collaboration will build upon our current understanding of how MPL works. Determining whether MPL has a novel mode of action could unlock substantial commercial value and will also help inform our selection of cancers that will most likely respond to MPL treatment in clinical trials.”
Hopkins added: “We are very pleased about the grant award and particularly delighted to be working with Dr Fairlie and the ONJCRI, which is home to many of Australia’s leading cancer researchers and clinicians.
“The translational capacity of this institute is formidable as it integrates both basic and clinical research with over 200 clinical trials in progress at any one time.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.